Letaplimab represents a distinct medical approach for treating complement-mediated conditions. This monoclonal antibody targets the C1q protein, a critical molecule of the complement system, effectively inhibit its https://diegoyjqx401661.blog5.net/92125468/letaplimab-a-innovative-clinical-method